OMEICOS Therapeutics GmbH

OMEICOS Therapeutics develops metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that addresses a new Mode of Action and that have the potential to treat inflammatory, cardiovascular, and other diseases. Epoxyeicosanoids, as a newly described class of bioactive lipid mediators, activate cell type-specific endogenous pathways that promote organ and tissue protection. OMEICOS’ small molecules are orally available and show improved biological activity and pharmacokinetic properties compared to their natural counterparts.
  • Mitarbeiterzahl

    14
  • Ausrichtungen
    • Therapie-Entwickler
  • Gegründet

    2013
  • Aktualisiert am

    30.05.2018